JP2003503038A - 乳を主成分とする予防的補助食品 - Google Patents
乳を主成分とする予防的補助食品Info
- Publication number
- JP2003503038A JP2003503038A JP2001505772A JP2001505772A JP2003503038A JP 2003503038 A JP2003503038 A JP 2003503038A JP 2001505772 A JP2001505772 A JP 2001505772A JP 2001505772 A JP2001505772 A JP 2001505772A JP 2003503038 A JP2003503038 A JP 2003503038A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- diabetes
- casein
- supplement
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 132
- 210000004080 milk Anatomy 0.000 title claims abstract description 132
- 239000008267 milk Substances 0.000 title claims abstract description 128
- 239000013589 supplement Substances 0.000 title claims description 43
- 230000003449 preventive effect Effects 0.000 title 1
- 102000011632 Caseins Human genes 0.000 claims abstract description 122
- 108010076119 Caseins Proteins 0.000 claims abstract description 122
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 92
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 90
- 239000005018 casein Substances 0.000 claims abstract description 69
- 235000013365 dairy product Nutrition 0.000 claims abstract description 64
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 60
- 235000021240 caseins Nutrition 0.000 claims abstract description 58
- 235000019152 folic acid Nutrition 0.000 claims abstract description 49
- 239000011724 folic acid Substances 0.000 claims abstract description 49
- 208000019553 vascular disease Diseases 0.000 claims abstract description 38
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 37
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 34
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 18
- 229960003237 betaine Drugs 0.000 claims abstract description 15
- 239000011677 pyridoxine Substances 0.000 claims abstract description 15
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 14
- 108010065875 beta-casomorphins Proteins 0.000 claims abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 6
- 230000036470 plasma concentration Effects 0.000 claims abstract description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 3
- 235000021247 β-casein Nutrition 0.000 claims description 63
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 43
- 229960000304 folic acid Drugs 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 41
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 241000283690 Bos taurus Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 14
- 230000029087 digestion Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000002792 vascular Effects 0.000 claims description 11
- 201000010193 neural tube defect Diseases 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 8
- 210000000936 intestine Anatomy 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 208000035581 susceptibility to neural tube defects Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000000153 supplemental effect Effects 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 25
- 235000005911 diet Nutrition 0.000 abstract description 17
- 208000029078 coronary artery disease Diseases 0.000 abstract description 12
- 230000037213 diet Effects 0.000 abstract description 11
- 230000007812 deficiency Effects 0.000 abstract description 6
- 229940014144 folate Drugs 0.000 abstract description 6
- 230000001364 causal effect Effects 0.000 abstract description 5
- 235000013339 cereals Nutrition 0.000 abstract description 5
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 229940021722 caseins Drugs 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 4
- 231100000517 death Toxicity 0.000 abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 210000000276 neural tube Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- RKYJTDSQXOMDAD-JKXTZXEVSA-N (2s,3s)-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CC=2C=CC(O)=CC=2)CCC1 RKYJTDSQXOMDAD-JKXTZXEVSA-N 0.000 description 17
- 108010020546 beta-casomorphin 7 Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- ADBHAJDGVKLXHK-UHFFFAOYSA-N Casomorphin Chemical compound CCC(C)C(C(O)=O)NC(=O)C1CCCN1C(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C1N(CCC1)C(=O)C(N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 ADBHAJDGVKLXHK-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- DJOMXNJPZLDSRB-NXPINLROSA-N (2s)-2-amino-4-[[(3s)-3-amino-3-carboxypropyl]disulfanyl]butanoic acid;(2s)-2-amino-4-sulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCS.OC(=O)[C@@H](N)CCSSCC[C@H](N)C(O)=O DJOMXNJPZLDSRB-NXPINLROSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 4
- 206010016880 Folate deficiency Diseases 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 201000010829 Spina bifida Diseases 0.000 description 4
- 208000006097 Spinal Dysraphism Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000020189 fortified milk Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- 235000015496 breakfast cereal Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000020603 homogenised milk Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000000945 opiatelike Effects 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RCMWNNJFKNDKQR-UHFFFAOYSA-N 2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid Chemical compound C1CCC(C(=O)NC(CC=2C=CC=CC=2)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 RCMWNNJFKNDKQR-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000035943 Aphagia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- KCTIFOCXAIUQQK-QXEWZRGKSA-N Ile-Pro-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O KCTIFOCXAIUQQK-QXEWZRGKSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- IALSFJSONJZBKB-HRCADAONSA-N Pro-Tyr-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)O IALSFJSONJZBKB-HRCADAONSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- NEDVJZNVOSNSHF-ZNHDNBJUSA-N [(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;nitrate Chemical compound [O-][N+]([O-])=O.C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2OC(=O)C(CO)C1=CC=CC=C1 NEDVJZNVOSNSHF-ZNHDNBJUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000020535 bottled fortified water Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000014651 chocolate spreads Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N cystathionine Chemical compound OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000030364 neural tube closure defect Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000019220 whole milk chocolate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ33650599 | 1999-06-29 | ||
| NZ336505 | 1999-06-29 | ||
| NZ504057 | 2000-04-18 | ||
| NZ50405700 | 2000-04-18 | ||
| PCT/NZ2000/000116 WO2001000047A1 (en) | 1999-06-29 | 2000-06-29 | Prophylactic dietary supplement based on milk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003503038A true JP2003503038A (ja) | 2003-01-28 |
Family
ID=26652075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001505772A Pending JP2003503038A (ja) | 1999-06-29 | 2000-06-29 | 乳を主成分とする予防的補助食品 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1196047A4 (zh) |
| JP (1) | JP2003503038A (zh) |
| CN (1) | CN1159984C (zh) |
| AU (1) | AU771754B2 (zh) |
| WO (1) | WO2001000047A1 (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010162035A (ja) * | 2002-07-03 | 2010-07-29 | A2 Corp Ltd | 生乳の脂肪酸の組成を変える方法 |
| KR20160044580A (ko) * | 2013-08-23 | 2016-04-25 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 ａ２ 및 혈중 글루코스 수준 |
| JP2016520611A (ja) * | 2013-05-31 | 2016-07-14 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２および腸の炎症の予防 |
| JP2016523958A (ja) * | 2013-07-12 | 2016-08-12 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２およびラクトース不耐性の症状の低減または予防 |
| JP2019532645A (ja) * | 2016-09-30 | 2019-11-14 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼイン類および腸微生物叢 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI114538B (fi) * | 2001-01-12 | 2004-11-15 | Finnfeeds Finland Ltd | Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen |
| ATE319330T1 (de) * | 2001-12-21 | 2006-03-15 | Dsm Ip Assets Bv | Modifierte methioninereiche nahrungsmittel und verfahren zu deren herstellung |
| US20060280802A1 (en) * | 2002-10-04 | 2006-12-14 | Campbell Julie H | Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
| PL2413952T3 (pl) | 2009-04-03 | 2017-08-31 | Nestec S.A. | Polepszenie promowania zdrowego doganiania wzrostu |
| EP2745709A1 (en) * | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Nutritional compositions with reduced beta-casein a1 and related methods |
| CN104940205A (zh) * | 2015-06-03 | 2015-09-30 | 华中科技大学 | 蝶酰谷氨酸在防治环境内分泌干扰物致子代糖尿病中的应用 |
| MX2018007819A (es) * | 2015-12-22 | 2018-12-17 | A2 Milk Co Ltd | Formula infantil que comprende peptidos de leche humana. |
| JP6256888B2 (ja) * | 2016-02-29 | 2018-01-10 | 高知県公立大学法人 | 健脳食品または健脳飲料およびこれらを投与する方法 |
| CN115553340A (zh) * | 2022-10-18 | 2023-01-03 | 北大荒完达山乳业股份有限公司 | 一种具有提高免疫力功能的降敏牛奶及其制备方法 |
| CN115708530A (zh) * | 2022-11-15 | 2023-02-24 | 北大荒完达山乳业股份有限公司 | 一种促进消化舒适性并稳定血糖的孕产妇配方奶粉及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
| WO1996036239A1 (en) * | 1995-05-16 | 1996-11-21 | Corran Norman Stuart Mclachlan | Food product and process |
| US5668173A (en) * | 1996-02-23 | 1997-09-16 | The Board Of Trustees Of The University Of Illinois Corp. | Method of increasing the conversion of homocysteine to methionine and uses thereof |
| IL117505A (en) * | 1996-03-15 | 1999-09-22 | Niva Shapira | Enriched dairy products |
| US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| US5993866A (en) * | 1997-09-12 | 1999-11-30 | Shapira; Niva | Process of making food products having reduced methionine ratios |
| ES2187115T3 (es) * | 1999-01-20 | 2003-05-16 | Nutricia Nv | Preparado para lactantes. |
-
2000
- 2000-06-29 EP EP00942589A patent/EP1196047A4/en not_active Withdrawn
- 2000-06-29 JP JP2001505772A patent/JP2003503038A/ja active Pending
- 2000-06-29 CN CNB008098174A patent/CN1159984C/zh not_active Expired - Lifetime
- 2000-06-29 AU AU57192/00A patent/AU771754B2/en not_active Expired
- 2000-06-29 WO PCT/NZ2000/000116 patent/WO2001000047A1/en not_active Application Discontinuation
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010162035A (ja) * | 2002-07-03 | 2010-07-29 | A2 Corp Ltd | 生乳の脂肪酸の組成を変える方法 |
| JP2016520611A (ja) * | 2013-05-31 | 2016-07-14 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２および腸の炎症の予防 |
| JP2016523958A (ja) * | 2013-07-12 | 2016-08-12 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２およびラクトース不耐性の症状の低減または予防 |
| JP6990154B2 (ja) | 2013-07-12 | 2022-01-12 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２およびラクトース不耐性の症状の低減または予防 |
| KR20160044580A (ko) * | 2013-08-23 | 2016-04-25 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 ａ２ 및 혈중 글루코스 수준 |
| JP2016532702A (ja) * | 2013-08-23 | 2016-10-20 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２および血中グルコースレベル |
| JP2019011342A (ja) * | 2013-08-23 | 2019-01-24 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２および血中グルコースレベル |
| KR20210022776A (ko) * | 2013-08-23 | 2021-03-03 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 ａ２ 및 혈중 글루코스 수준 |
| KR102270059B1 (ko) * | 2013-08-23 | 2021-06-28 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 ａ２ 및 혈중 글루코스 수준 |
| JP7082551B2 (ja) | 2013-08-23 | 2022-06-08 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２および血中グルコースレベル |
| KR102626825B1 (ko) * | 2013-08-23 | 2024-01-17 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 ａ２ 및 혈중 글루코스 수준 |
| JP2019532645A (ja) * | 2016-09-30 | 2019-11-14 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼイン類および腸微生物叢 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1196047A4 (en) | 2004-12-22 |
| CN1159984C (zh) | 2004-08-04 |
| CN1368853A (zh) | 2002-09-11 |
| WO2001000047A1 (en) | 2001-01-04 |
| AU5719200A (en) | 2001-01-31 |
| AU771754B2 (en) | 2004-04-01 |
| EP1196047A1 (en) | 2002-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wren et al. | Ghrelin enhances appetite and increases food intake in humans | |
| Koletzko et al. | Growth, development and differentiation: a functional food science approach | |
| Rudloff et al. | Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition | |
| JP2003503038A (ja) | 乳を主成分とする予防的補助食品 | |
| KR100996985B1 (ko) | 글루카곤양 펩티드-１ 분비 촉진제, 글루카곤양 펩티드-１분비 촉진용 음식품, 식후 혈당값 상승 억제제 및 식후혈당값 상승 억제용 음식품 | |
| MX2011010454A (es) | Mejoramiento en la promocion de la sana recuperacion del crecimiento. | |
| WO2011105435A1 (ja) | 摂食障害治療剤 | |
| US8921310B2 (en) | Method for accelerating mammalian body fat metabolism | |
| AU2002321557B2 (en) | Use of leptin for infant with low birth weight for prevention of obesity | |
| JP7433220B2 (ja) | 月経随伴症状の処置のための組成物 | |
| AU2007247025B2 (en) | Use of alpha-lactalbumin for regulation of glycemia | |
| AU2002321557A1 (en) | Use of leptin for infant with low birth weight for prevention of obesity | |
| Tiwari et al. | Nutritional Values and Therapeutic Uses of Capra hircus Milk. | |
| RU2305417C2 (ru) | Модифицированные пищевые продукты, богатые метионином, и способ их производства | |
| Daly et al. | Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit? | |
| NZ516712A (en) | Prophylactic dietary supplement based on milk | |
| JP2003511097A (ja) | 栄養補助剤 | |
| Keskin et al. | Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria | |
| Naples Federico | Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria | |
| JP2021181408A (ja) | パーキンソン病治療用組成物及びカテコール類血中濃度向上用組成物 | |
| JP2020005598A (ja) | 起床時コルチゾール濃度調節用組成物 | |
| HACKENG et al. | Primary somatomedin deficiency | |
| JP5827783B2 (ja) | 月経痛緩和剤 | |
| BERRY et al. | 39 phenylketonuria and Maternal phenylketonuria | |
| TW201924713A (zh) | 改善慢性發炎用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050610 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050610 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050627 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050613 |